Insulin resistance test Canada: Where and how to get tested (2026 guide)

Introduction — a shocking Canadian statistic

Insulin resistance (IR) precedes many cases of type 2 diabetes and contributes to cardiovascular risk. Recent national data show roughly 8.0% of Canadians aged 18+ reported having diabetes in 2023, with many more carrying prediabetes — a sign that insulin resistance is common and often under‑detected. This underlines the public‑health importance of knowing where and how Canadians can get tested for IR. ([www150.statcan.gc.ca](https://www150.statcan.gc.ca/n1/pub/82-570-x/82-570-x2024001-eng.pdf?utm_source=openai))

What is insulin resistance, and why does it matter?

Insulin resistance means tissues (muscle, liver, fat) respond less well to insulin, so the pancreas produces more insulin to keep blood sugar normal. Over time this compensatory hyperinsulinaemia can fail, blood glucose rises and prediabetes or type 2 diabetes develops. Detecting insulin resistance early offers a window where lifestyle interventions are most effective. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542105/?utm_source=openai))

Tests used in Canada to assess insulin resistance and dysglycaemia

Standard screening tests (recommended by Diabetes Canada)

Diabetes Canada’s Clinical Practice Guidelines recommend using fasting plasma glucose (FPG), hemoglobin A1c (A1C) and a 75 g oral glucose tolerance test (OGTT) for screening and diagnosis. These are widely accepted by family doctors and provincial labs for identifying prediabetes and diabetes. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/health-care-provider-tools/screening-and-diagnosis-algorithm?utm_source=openai))

Fasting insulin and HOMA‑IR

HOMA‑IR (Homeostatic Model Assessment of Insulin Resistance) is a simple index calculated using fasting insulin and fasting glucose. Formula (HOMA1): HOMA‑IR = (fasting insulin [µU/mL] × fasting glucose [mmol/L]) / 22.5. This gives an estimate of insulin sensitivity and can reveal hyperinsulinaemia before A1C or fasting glucose rise. Remember: insulin assays and cut‑offs vary — use trends and clinical context rather than a single absolute number. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542105/?utm_source=openai))

OGTT with insulin sampling

OGTT‑with‑insulin captures the dynamic insulin response and is useful for complex or equivocal cases (PCOS, atypical diabetes presentations), but it is more time‑consuming and usually performed by specialists or in research settings. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35676014/?utm_source=openai))

Other indices (TyG, QUICKI, CGM)

Indices like TyG (triglyceride × glucose) and QUICKI exist as surrogate markers; CGM is increasingly used to detect early post‑prandial dysglycaemia. Systematic reviews are refining their roles but they remain adjuncts rather than standard population screening tests. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7085845/?utm_source=openai))

How accurate and reliable are these tests?

HOMA‑IR correlates with gold‑standard clamps reasonably well at a population level but has limitations for individual diagnosis due to assay variability, differences across ethnic groups and lack of universal cut‑offs. Systematic reviews conclude HOMA‑IR is useful for research and for detecting trends clinically, but clinicians should combine it with other tests and risk factors for decision‑making. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542105/?utm_source=openai))

Where to get tested across Canada — practical options

1. Family doctor / primary care — the usual route. They can order FPG, A1C, OGTT and fasting insulin when clinically appropriate. Publicly funded tests are usually covered when medically justified. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/getmedia/6c07d660-33a6-4cfa-abb0-e521eb4bb67d/2024-CPG-Quick-Reference-Guide_1.pdf?utm_source=openai))
2. Walk‑in clinics and community/hospital labs — accept clinician requisitions; schedules and availability vary by province and facility. ([myhealth.alberta.ca](https://myhealth.alberta.ca/Find-Health-Care/Facilities/Pages/Profile.aspx?facilityid=2&serviceid=1000871&utm_source=openai))
3. Private / DTC labs — if you need a test without wait or without a requisition, companies such as JustLabs and other private services offer fasting insulin and related panels for a fee (availability and price vary). These services ship and have collection sites across provinces. Validate units and methods before ordering. ([justlabs.health](https://justlabs.health/tests/insulin-fasting?utm_source=openai))
4. Endocrinology referral and specialist testing — for complex cases, endocrinologists can order OGTT‑with‑insulin or arrange specialized metabolic testing. ([cmaj.ca](https://www.cmaj.ca/sites/default/files/additional-assets/site/pdfs/focus_on_diabetes.pdf?utm_source=openai))

Provincial practicalities

Provincial programs differ: public lab testing requires a clinician’s requisition and is generally covered when medically necessary; private tests are available across Canada for those willing to pay. Examples include Ontario’s OHIP guidance on lab coverage and Alberta Health Services’ lab service descriptions — check your province’s health site for specifics. Many private labs operate from BC to Newfoundland, but coverage, requisition rules and turnaround times vary. ([img1.wsimg.com](https://img1.wsimg.com/blobby/go/47c78ccf-d12f-481a-82c2-f7dc3b6ca738/downloads/safofikafaxili.pdf?utm_source=openai))

Interpreting results — practical guidance

• Always confirm lab units: insulin reported as µU/mL or pmol/L (1 µU/mL ≈ 6 pmol/L). Use µU/mL with glucose in mmol/L for HOMA‑IR. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542105/?utm_source=openai))
• There is no single universal HOMA‑IR cut‑off; studies use different thresholds (many >2–2.5 as suggestive). Serial measures and clinical context are most helpful. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12411212/?utm_source=openai))
• Normal A1C/fasting glucose does not always exclude early insulin resistance — consider OGTT, fasting insulin/HOMA‑IR or CGM in at‑risk patients. ([diabetes.ca](https://www.diabetes.ca/health-care-providers/clinical-practice-guidelines/chapter-4?utm_source=openai))

What to do if insulin resistance is likely

1. Talk to your health provider about follow‑up testing and risk — diabetes education, dietitian referral and monitoring may be recommended. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/getmedia/6c07d660-33a6-4cfa-abb0-e521eb4bb67d/2024-CPG-Quick-Reference-Guide_1.pdf?utm_source=openai))
2. Evidence‑based lifestyle changes: moderate weight loss (5–10%), combined aerobic and resistance exercise and dietary quality (Mediterranean/DASH) reduce insulin resistance. Some intermittent fasting/time‑restricted eating protocols reduce HOMA‑IR in trials. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35371260/?utm_source=openai))
3. Medication (metformin) may be considered in high‑risk or persistent prediabetes — discuss with your clinician. Provincial coverage for medications varies. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/getmedia/6c07d660-33a6-4cfa-abb0-e521eb4bb67d/2024-CPG-Quick-Reference-Guide_1.pdf?utm_source=openai))

How Feel Great may fit into a Canadian plan

The Feel Great system combines a soluble fibre matrix (Balance) that may blunt post‑meal glucose peaks, a yerba mate extract (Unimate) rich in chlorogenic acids that has modest RCT evidence for improving HOMA‑IR and glycaemia in some groups, and a practical 4‑4‑12 time‑restricted eating protocol. Clinical trials of time‑restricted eating and yerba mate show potential to reduce fasting insulin and HOMA‑IR in at‑risk adults. These tools are supportive lifestyle options — they are not drugs and should be discussed with your provider. Check Health Canada’s LNHPD for Natural Product Numbers (NPN) before buying supplements. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35371260/?utm_source=openai))

People also ask

FAQ

References & Scientific Sources

1. Public Health Agency of Canada — Snapshot of Diabetes in Canada, 2023. ([canada.ca](https://www.canada.ca/en/public-health/services/publications/diseases-conditions/snapshot-diabetes-canada-2023.html?utm_source=openai))
2. Health Infobase — Diabetes in Canada interactive report (Health Canada / PHAC). ([health-infobase.canada.ca](https://health-infobase.canada.ca/diabetes/?utm_source=openai))
3. Statistics Canada — Diabetes among Canadian adults. ([statcan.gc.ca](https://www.statcan.gc.ca/o1/en/plus/5103-diabetes-among-canadian-adults?utm_source=openai))
4. Diabetes Canada — Clinical Practice Guidelines, Screening & Diagnosis. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/health-care-provider-tools/screening-and-diagnosis-algorithm?utm_source=openai))
5. CIHI — Diabetes outcomes, hospitalizations and equity analyses. ([cihi.ca](https://www.cihi.ca/en/equity-in-diabetes-care-a-focus-on-lower-limb-amputation/amputations-signal-opportunities-to-improve-diabetes-care-and-reduce-system-costs?utm_source=openai))
6. Measuring and estimating insulin resistance in clinical and research settings — NCBI / Endotext review. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542105/?utm_source=openai))
7. HOMA‑IR systematic review and meta‑analysis (PubMed). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36181637/?utm_source=openai))
8. Intermittent fasting systematic review and meta‑analysis (impact on HOMA‑IR). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35371260/?utm_source=openai))
9. Yerba mate systematic review / RCT evidence (glycaemia, HOMA‑IR). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41244043/?utm_source=openai))
10. TyG index diagnostic accuracy systematic review. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7085845/?utm_source=openai))
11. Health Canada — Licensed Natural Health Products Database (LNHPD). ([canada.ca](https://www.canada.ca/en/health-canada/services/drugs-health-products/natural-non-prescription/applications-submissions/product-licensing/licensed-natural-health-products-database.html?utm_source=openai))
12. JustLabs (example Canadian DTC lab offering fasting insulin). ([justlabs.health](https://justlabs.health/tests/insulin-fasting?utm_source=openai))

Medical disclaimer: This article is informational and not a substitute for professional medical advice. Tests, interpretation and therapeutic decisions should be made with a licensed healthcare provider. For urgent concerns, contact your family doctor or local emergency services. The Feel Great system is offered as a supportive lifestyle tool and is not a medication. Check Health Canada’s LNHPD for NPNs and speak with your clinician before starting supplements. ([canada.ca](https://www.canada.ca/en/health-canada/services/drugs-health-products/natural-non-prescription/applications-submissions/product-licensing/licensed-natural-health-products-database.html?utm_source=openai))

Introduction — a striking Canadian number

Insulin resistance is the metabolic disturbance that often comes before type 2 diabetes and many cardiovascular conditions. In recent national estimates about 8.0% of Canadians aged 18 and older reported living with diabetes in 2023, while measured prediabetes is also common — meaning many Canadians have early insulin dysfunction that could be identified sooner. These are not just individual problems: diabetes and related complications drive major health system costs in Canada. ([www150.statcan.gc.ca](https://www150.statcan.gc.ca/n1/pub/82-570-x/82-570-x2024001-eng.pdf?utm_source=openai))

Why test for insulin resistance (IR)?

Testing for insulin resistance can find metabolic dysfunction before average blood sugars (A1C) or fasting glucose move into the prediabetes/diabetes ranges. Early detection gives a window of opportunity: lifestyle changes often have greater impact earlier in the course of metabolic decline. However, opinions differ on who should be tested and which test is ideal — national screening guidance in Canada prioritizes FPG, A1C and OGTT but many clinicians and researchers use fasting insulin/HOMA‑IR or OGTT‑with‑insulin in selected cases. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/health-care-provider-tools/screening-and-diagnosis-algorithm?utm_source=openai))

Which tests are used to detect insulin resistance in Canada?

1) Routine screening tests used across Canada (Diabetes Canada)

Diabetes Canada recommends: fasting plasma glucose (FPG), hemoglobin A1c (A1C) and a 75 g oral glucose tolerance test (OGTT) for screening and diagnosis of prediabetes and type 2 diabetes. These tests define impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and A1C‑based prediabetes. They are the backbone of provincial screening programmes and are widely available through primary care and hospital/community labs. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/health-care-provider-tools/screening-and-diagnosis-algorithm?utm_source=openai))

2) Fasting insulin and HOMA‑IR (fast, inexpensive estimate)

HOMA‑IR formula (HOMA1): HOMA‑IR = (fasting insulin [µU/mL] × fasting glucose [mmol/L]) / 22.5. Use insulin measured in micro‑units per millilitre (µU/mL) and glucose in mmol/L. A practical example: fasting glucose 5.0 mmol/L with fasting insulin 15 µU/mL → HOMA‑IR = (15 × 5) / 22.5 = 3.33. Many studies and clinics consider values above ~2–2.5 or higher as suggestive of insulin resistance, but cut‑offs vary by age, sex and ethnicity — there is no single universal HOMA‑IR threshold. Interpret results with your clinician. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542105/?utm_source=openai))

3) OGTT with insulin sampling (dynamic test)

A full OGTT with insulin measures how insulin rises and falls after a 75 g glucose load (often measured at fasting, 30, 60 and 120 minutes). OGTT‑insulin provides dynamic information about insulin secretion and peripheral sensitivity — more informative than fasting insulin alone, but more time‑consuming and usually reserved for research, complex cases (for example PCOS or atypical presentations) or specialist assessment. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35676014/?utm_source=openai))

4) Gold standard: euglycaemic hyperinsulinaemic clamp (research only)

The insulin clamp is the research gold standard for measuring insulin sensitivity but is time‑intensive and only available in research or specialist centres. For clinical practice, validated surrogate measures such as HOMA‑IR, QUICKI, TyG index and OGTT‑derived metrics are more practical. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK278954/?utm_source=openai))

5) Emerging/adjunct tests: TyG index, CGM

The triglyceride‑glucose (TyG) index and measures from continuous glucose monitoring (CGM) are being studied as screening tools for early dysglycaemia and insulin resistance; the evidence base is growing with several systematic reviews describing diagnostic performance and limitations. CGM may detect post‑prandial dysglycaemia that fasting tests miss. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7085845/?utm_source=openai))

How accurate are HOMA‑IR and fasting insulin?

HOMA‑IR correlates reasonably with clamp measures at the population level and is widely used in clinical research as a practical index of hepatic/whole‑body insulin resistance. However, cross‑study comparisons are complicated by different assay methods for insulin, ethnic differences and varying cut‑offs. Systematic reviews show that HOMA‑IR can predict metabolic risk but emphasise the need for population‑specific thresholds. In short: HOMA‑IR is useful for screening and monitoring trends, but clinical decisions should combine HOMA‑IR with other tests, risk factors and clinical findings. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542105/?utm_source=openai))

Where to get an insulin resistance test in Canada — step‑by‑step

1. Start with your primary care provider (family doctor / nurse practitioner) — they can order FPG, A1C, OGTT and fasting insulin when clinically indicated. Public provincial coverage usually pays for medically necessary lab tests ordered by a clinician; check your province for details. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/getmedia/6c07d660-33a6-4cfa-abb0-e521eb4bb67d/2024-CPG-Quick-Reference-Guide_1.pdf?utm_source=openai))
2. Walk‑in clinics and community labs — most community labs (hospital labs, provincial lab networks) accept clinician requisitions; some tests may require an appointment and specific fasting instructions. Provincial lab networks (Alberta Health Services, BC’s Laboratory Services, Ontario community labs) are the common routes. ([myhealth.alberta.ca](https://myhealth.alberta.ca/Find-Health-Care/Facilities/Pages/Profile.aspx?facilityid=2&serviceid=1000871&utm_source=openai))
3. Private / direct‑to‑consumer (DTC) labs — companies such as JustLabs and independent pathology services sell fasting insulin tests or panels if you prefer to pay privately or lack timely access to a requisition. Prices vary (example: JustLabs lists fasting insulin testing options starting at modest prices). If using a private test, confirm the assay units (µU/mL) and lab reference range. ([justlabs.health](https://justlabs.health/tests/insulin-fasting?utm_source=openai))
4. Endocrinology referral — if results are unclear, you have PCOS, worsening metabolic disease, or complex needs, your family doctor can refer to an endocrinologist who may order OGTT‑with‑insulin, clamp testing (rare) or specialist metabolic assessments. ([cmaj.ca](https://www.cmaj.ca/sites/default/files/additional-assets/site/pdfs/focus_on_diabetes.pdf?utm_source=openai))
5. What to expect on the day — fasting 8–12 hours for fasting glucose/insulin; avoid strenuous exercise, alcohol and caffeine for 24 hours when possible; bring a list of medications (some alter insulin levels). Ask the lab which units they report so you can calculate HOMA‑IR correctly. ([testing.com](https://www.testing.com/tests/fasting-insulin-test/?utm_source=openai))

Provincial differences — practical points for Ontario, Alberta and BC

Coverage models and how you access testing differ by province. Publicly funded lab testing generally requires a clinician’s requisition and is covered when medically necessary. For example, Ontario’s laboratory services guidance lists which community lab services are covered by OHIP and notes that some specialised or non‑routine tests may not be covered; Alberta’s laboratory services similarly accept clinician orders via Alberta Health Services. If you need faster access or a test not covered, private DTC labs operate across provinces (shipping / collection points from BC to Newfoundland). Always check local lab menus and confirm whether fasting insulin is on the standard public panel. ([img1.wsimg.com](https://img1.wsimg.com/blobby/go/47c78ccf-d12f-481a-82c2-f7dc3b6ca738/downloads/safofikafaxili.pdf?utm_source=openai))

Interpreting results — practical thresholds and pitfalls

Key interpretation points:

• Units matter: fasting insulin is typically reported in µU/mL (or pmol/L — conversion: 1 µU/mL ≈ 6 pmol/L). Use insulin in µU/mL with glucose in mmol/L in the HOMA‑IR formula above. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542105/?utm_source=openai))
• HOMA‑IR variability: commonly used cut‑offs range from ~1.5–3.0 depending on population; recent systematic reviews stress that thresholds are context‑dependent. Use trends (serial tests) rather than a single absolute number when possible. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12411212/?utm_source=openai))
• False reassurance: normal A1C or fasting glucose does not always exclude early IR — OGTT, fasting insulin or CGM can reveal earlier abnormalities. Conversely, a single elevated fasting insulin without context is hard to act on. ([diabetes.ca](https://www.diabetes.ca/health-care-providers/clinical-practice-guidelines/chapter-4?utm_source=openai))

Which test should you choose? (short comparison)

What to do if your test suggests insulin resistance

1. Discuss results with your primary care team — they will put labs in context with risk factors (age, BMI, family history, ethnicity). ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/getmedia/6c07d660-33a6-4cfa-abb0-e521eb4bb67d/2024-CPG-Quick-Reference-Guide_1.pdf?utm_source=openai))
2. Start evidence‑based lifestyle steps: weight loss (5–10% can improve insulin sensitivity), increased physical activity (aerobic + resistance), and dietary adjustments — Mediterranean/DASH‑style patterns show benefit. Intermittent time‑restricted eating (e.g., 4‑4‑12 style windows) and supervised fasting protocols have evidence for improving HOMA‑IR in some trials. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35371260/?utm_source=openai))
3. Referral to diabetes education, dietitian or endocrinology if risk is high (A1C in prediabetes range or multiple cardiometabolic risk factors). Diabetes Canada provides clear follow‑up and prevention pathways. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/health-care-provider-tools/screening-and-diagnosis-algorithm?utm_source=openai))
4. Medications such as metformin may be considered in high‑risk people — discuss risks, benefits and provincial coverage with your clinician. (Clinical practice guidelines determine when medication is appropriate.) ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/getmedia/6c07d660-33a6-4cfa-abb0-e521eb4bb67d/2024-CPG-Quick-Reference-Guide_1.pdf?utm_source=openai))

How the Feel Great system fits (supportive, not a medication)

For Canadians looking for structured, evidence‑informed supportive tools, the Feel Great system combines dietary fibre matrices (Balance), yerba mate extract (Unimate), and the 4‑4‑12 intermittent eating window. These components may help people manage post‑meal glucose responses and energy/clarity and can be used alongside medical care. For example, meta‑analyses and RCTs show that time‑restricted eating and intermittent fasting can reduce HOMA‑IR and fasting insulin in metabolically at‑risk adults, and there is randomized evidence that yerba mate / chlorogenic acid‑containing products produce modest improvements in HOMA‑IR and fasting glucose in some populations. Always discuss supplements and dietary programmes with your healthcare provider; check Health Canada’s Licensed Natural Health Products Database (LNHPD) for NPN licensing before purchase. Feel Great is a lifestyle support system — not a medication — and should be used with routine medical care. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35371260/?utm_source=openai))

People‑Also‑Ask

FAQ

References & Scientific Sources

1. Public Health Agency of Canada — Snapshot of Diabetes in Canada, 2023. ([canada.ca](https://www.canada.ca/en/public-health/services/publications/diseases-conditions/snapshot-diabetes-canada-2023.html?utm_source=openai))
2. Health Infobase — Diabetes in Canada interactive report (Health Canada / PHAC). ([health-infobase.canada.ca](https://health-infobase.canada.ca/diabetes/?utm_source=openai))
3. Statistics Canada — Diabetes among Canadian adults (analysis and tables). ([statcan.gc.ca](https://www.statcan.gc.ca/o1/en/plus/5103-diabetes-among-canadian-adults?utm_source=openai))
4. Diabetes Canada — Clinical Practice Guidelines, Screening & Diagnosis (CPG chapters / Quick Reference). ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/health-care-provider-tools/screening-and-diagnosis-algorithm?utm_source=openai))
5. Canadian Institute for Health Information (CIHI) — Equity in diabetes care and diabetes‑associated hospitalizations/amputations. ([cihi.ca](https://www.cihi.ca/en/equity-in-diabetes-care-a-focus-on-lower-limb-amputation/amputations-signal-opportunities-to-improve-diabetes-care-and-reduce-system-costs?utm_source=openai))
6. Measuring and estimating insulin resistance in clinical and research settings — review (NCBI / Endotext). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542105/?utm_source=openai))
7. HOMA‑IR systematic review and meta‑analysis (PubMed): HOMA as predictor of outcomes. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36181637/?utm_source=openai))
8. Systematic review/meta‑analysis — intermittent fasting and insulin resistance improvements. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35371260/?utm_source=openai))
9. Yerba mate systematic review / RCT evidence (effects on HOMA‑IR, glycaemia). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41244043/?utm_source=openai))
10. TyG index diagnostic accuracy systematic review. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7085845/?utm_source=openai))
11. Licensed Natural Health Products Database (Health Canada — LNHPD) — checking NPNs. ([canada.ca](https://www.canada.ca/en/health-canada/services/drugs-health-products/natural-non-prescription/applications-submissions/product-licensing/licensed-natural-health-products-database.html?utm_source=openai))
12. JustLabs — fasting insulin direct‑to‑consumer testing (example pricing and availability in Canada). ([justlabs.health](https://justlabs.health/tests/insulin-fasting?utm_source=openai))

Medical disclaimer: This article is for Canadian general information only and does not replace personalised medical advice. Tests, interpretation and treatment should be done with a licensed healthcare provider. For urgent issues, contact your family doctor, local emergency services or call 811 in most provinces for health navigation. The Feel Great system is described here as a supportive lifestyle option; it is not a drug and should not replace medical care. See Health Canada Licensed Natural Health Products Database for NPN and safety information before using any supplement. ([canada.ca](https://www.canada.ca/en/health-canada/services/drugs-health-products/natural-non-prescription/applications-submissions/product-licensing/licensed-natural-health-products-database.html?utm_source=openai))